Metoprolol Tartrate Injection

This product competitively inhibits the action of catecholamines at the adrenaline beta receptor site, mainly by selectively inhibiting cardiac beta 1 receptors, making them in an inhibited state, but it has a weaker effect on beta 2 receptors. 1 Reduces heart rate and cardiac output at rest and during exercise. 2 Reduces systolic blood pressure during exercise. 3 Inhibits tachycardia caused by isoproterenol. 4 Reduces reflex orthostatic tachycardia. 5 In asthmatic patients, metoprolol tartrate reduces FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) significantly less than non-selective beta blockers (such as propranolol).

Metoprolol tartrate

Supraventricular tachyarrhythmias. Prevention and treatment of myocardial ischemia, tachyarrhythmias and chest pain in patients with confirmed or suspected acute myocardial infarction.

1. Intravenous administration of Betaloc should be carried out under the guidance of an experienced physician. At the same time, the patient's blood pressure and electrocardiogram should be carefully monitored, and resuscitation facilities should be available. 2. Supraventricular tachyarrhythmia: Initially, intravenous administration is performed at a rate of 1-2 mg/min, and the dosage can reach 5 mg (5 ml); if the condition requires, the injection can be repeated at intervals of 5 minutes, with a total dose of 10-15 mg (4-6 hours after intravenous injection, the arrhythmia has been controlled, and oral preparations are used to maintain it, 2-3 times a day, and each dose does not exceed 50 mg). 3. Prevention and treatment of myocardial ischemia, tachyarrhythmia and chest pain in patients with confirmed or suspected acute myocardial infarction: Immediate intravenous administration of 5 mg (5 ml). This dose can be repeated after an interval of 2 minutes until the maximum dose is 5 mg (5 ml). Patients with the following conditions cannot be given intravenously immediately: heart rate < 70 beats/min, systolic blood pressure < 110 mmHg, or first-degree atrioventricular block. For further treatment options (oral medication), please refer to the relevant instructions for metoprolol tartrate tablets. If treatment must be interrupted, the dosage should be reduced as gradually as possible and the drug should be discontinued after at least 1 to 2 weeks. Otherwise, angina pectoris may be aggravated and the risk of myocardial infarction may be increased. Patients who intend to discontinue metoprolol tartrate before surgery should discontinue it at least 24 hours before surgery; special cases such as patients with hyperthyroidism or pheochromocytoma may be exceptions. 4 Drug compatibility: Metoprolol tartrate injection 1mg/ml, large doses can be up to 40mg, can be added to 1000ml of the following intravenous injections for drip infusion: 0.9% sodium chloride, 10% glucose, 5% glucose, Ringer's injection, Ringer's-dextrose solution and acetic Ringer's solution. The injection should be used within 12 hours after dilution. Metoprolol tartrate should not be added to dextran 70 plasma substitute for drip infusion.

Some cases experience low blood pressure, bradycardia, dizziness and discomfort.

Ⅱdeg; or Ⅲdeg; atrioventricular block, cardiogenic shock, severe bradycardia (heart rate less than 60 beats/min), systolic blood pressure less than 12kpa, heart failure, sick sinus syndrome and pregnant women are contraindicated. Use with caution in patients with asthma, diabetes, hyperthyroidism and liver and kidney damage.

Precautions during pregnancy and lactation: Pregnant women are prohibited from using

1. Patients with catecholamine depletion (such as reserpine) may experience dizziness or postural hypotension when used in combination with this product. 2. Nifedipine and diltiazem inhibit myocardial contraction, relax smooth muscle, and have different degrees of blood pressure lowering effects. They should not be used in combination with beta-receptor blockers. 3. When used in combination with clonidine and the drug must be discontinued, this product must be discontinued first, and then clonidine should be gradually discontinued after a few days to avoid blood pressure fluctuations. 4. When used in combination with digitalis glycosides, atrioventricular block may occur and cause a slow heart rate, so close observation is required. 5. When used in combination with adrenaline, phenylephrine or sympathomimetic amines, it may cause significant hypertension, slow heart rate, and atrioventricular block, so close observation is required. 6. It can enhance the efficacy of non-depolarizing muscle relaxants such as tubocurarine chloride and galactodonium iodide, and the duration of effect is also prolonged. 7. It can affect blood sugar levels, so when used in combination with hypoglycemic drugs, the latter's dose must be adjusted. 8 When used with isoproterenol or xanthine, the efficacy of the latter two may be weakened. 9 When used with monoamine oxidase inhibitors, it may cause extreme hypotension and is contraindicated. 10 When used with phenothiazines, the blood concentrations of both drugs may increase. 11 When used with reserpine, the effects of the two drugs are additive, the beta-receptor blocking effect is enhanced, and bradycardia and hypotension may occur.

Keep away from light and store in a sealed container.

2ml: Metoprolol tartrate 2mg and sodium chloride 18mg

Shaanxi Bosen Biological Pharmaceutical Group Co., Ltd.

• Founded in:

  2002-12-12

• Address:

  No. 7, Chuangxin Road, New Industrial Park, High-tech Zone, Xi'an, Shaanxi Province

• Tax NO.:

  91610000745007979F

• Registered Funds:

  171 million yuan

• Website:

  Log in to view

• Email:

  Log in to view